8-K: Heron Therapeutics Partners with CrossLink to Expand ZYNRELEF Sales Network

Heron Therapeutics has partnered with CrossLink Life Sciences to significantly expand the sales and promotion of their non-opioid pain relief product, ZYNRELEF, in the United States.

Summary

• Heron Therapeutics has entered into a co-promotion agreement with CrossLink Network, LLC to expand the sales of ZYNRELEF.
• CrossLink will co-promote ZYNRELEF on a co-exclusive basis for all FDA-approved surgical indications in the U.S.
• CrossLink is committed to having at least 325 sales representatives promoting ZYNRELEF by July 1, 2024, and at least 650 by January 1, 2025.
• Heron will pay CrossLink a fixed fee per vial based on growth over a pre-determined baseline, plus up to $5 million for meeting sales-growth milestones.
• Heron will also award Crosslink up to 1,666,670 shares of common stock based on performance criteria.
• The agreement has an initial term until December 31, 2028, with automatic one-year renewals unless terminated.
• The partnership aims to expand access to ZYNRELEF for orthopedic surgery patients.
• CrossLink is the largest private orthopedic, spine, and sports medicine device distributorship in the U.S.

Sentiment

Score: 8

Explanation: The document is positive due to the strategic partnership and expansion of sales efforts, but there are some risks and uncertainties associated with the agreement.

Positives

• The partnership with CrossLink is expected to significantly expand the reach and sales of ZYNRELEF.
• The addition of 650 sales representatives will greatly increase the promotional effort for ZYNRELEF.
• CrossLink's expertise in the orthopedic market should drive adoption of ZYNRELEF.
• The fixed-fee per vial compensation structure incentivizes CrossLink to drive sales growth.
• The potential for up to $5 million in milestone payments further motivates CrossLink to achieve sales targets.
• The stock award to Crosslink aligns their interests with Heron's success.
• ZYNRELEF is a unique product with proven benefits in reducing post-operative pain and opioid use.

Negatives

• The agreement includes a potential dilution of Heron's stock through the issuance of up to 1,666,670 shares to Crosslink.
• The company is committed to paying Crosslink certain cash base compensation on a fixed-fee per vial basis, based on growth over a pre-determined baseline period.
• The company is committed to paying Crosslink certain cash compensation in an amount up to $5,000,000 throughout the term of the Co-Promotion Agreement if certain year-over-year sales-growth milestones are met.
• The agreement can be terminated by either party with 90 days notice at the end of the initial or renewal periods, which could disrupt the sales strategy.

Risks

• The success of the partnership depends on CrossLink's ability to effectively promote ZYNRELEF.
• There is a risk that the sales milestones may not be met, impacting the potential compensation for CrossLink.
• The agreement could be terminated early under certain conditions, potentially disrupting the sales strategy.
• The company is subject to risks and uncertainties related to market conditions, potential market opportunities for ZYNRELEF, and the timing of the FDA's review process.
• The company is subject to risks and uncertainties related to the timing of the company's development of the VAN program and the timing of the company's submission of the PAS to the FDA for the VAN.

Future Outlook

The partnership is expected to expand access to ZYNRELEF and increase its adoption in orthopedic surgery, with a potential expansion of the ZYNRELEF label and the vial-access needle (VAN) which will streamline the product preparation.

Management Comments

• Craig Collard, Chief Executive Officer of Heron, stated that the partnership will allow Heron to expand access to this pain-reducing product for orthopedic surgery patients.
• Thomas Fleetwood, Chief Executive Officer of CrossLink, expressed excitement about the partnership and the potential expansion of the ZYNRELEF label and the vial-access needle (VAN).

Industry Context

This partnership reflects a trend in the pharmaceutical industry to leverage specialized sales forces to expand the reach of niche products, particularly in the orthopedic and pain management sectors. It also highlights the growing demand for non-opioid pain management solutions.

Comparison to Industry Standards

• The agreement with CrossLink is similar to other co-promotion agreements in the pharmaceutical industry, where companies partner to leverage each other's strengths.
• The use of a fixed-fee per vial compensation structure is a common practice in such agreements, aligning incentives for both parties.
• The commitment to a specific number of sales representatives is a key performance indicator, similar to other sales-focused partnerships.
• The potential for milestone payments is a standard practice to incentivize sales growth.
• The stock award is a less common but not unheard of method to align the interests of the partner with the company's long-term success.

Stakeholder Impact

• Shareholders may see a positive impact from increased sales and revenue.
• Employees may benefit from the growth of the company and potential job opportunities.
• Healthcare providers will have increased access to ZYNRELEF for their patients.
• Patients will benefit from the availability of a non-opioid pain management option.

Next Steps

• CrossLink will begin the phased rollout of the sales expansion, starting regionally and then expanding nationally.
• Heron will continue to work with the FDA on the sNDA for ZYNRELEF and the PAS for the VAN.
• Heron will monitor the performance of the partnership and make adjustments as needed.

Key Dates

Keywords

ZYNRELEF, Heron Therapeutics, CrossLink Life Sciences, Co-Promotion Agreement, Orthopedic, Pain Management, Sales Expansion, Post-Operative Pain, Bupivacaine, Meloxicam